# EDGAR Filing Document

**Accession Number:** 0001339970
**File Stem:** 0000000000-25-008523
**Filing Date:** 2025-8
**Character Count:** 2209
**Document Hash:** e6ba4693e69511c61fd675d95718c054
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008523.hdr.sgml**: 20250917

**ACCESSION NUMBER**: 0000000000-25-008523

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250813

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** aTYR PHARMA INC
- **CENTRAL INDEX KEY:** 0001339970
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 203435077
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-289360

**BUSINESS ADDRESS:**
- **STREET 1:** 10240 SORRENTO VALLEY ROAD
- **STREET 2:** SUITE 300
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 8587318389

**MAIL ADDRESS:**
- **STREET 1:** 10240 SORRENTO VALLEY ROAD
- **STREET 2:** SUITE 300
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001339970-25-000011

## Text-Extract

```

                                                           August 13, 2025

Sanjay Shukla
Chief Executive Officer
aTyr Pharma, Inc.
10240 Sorrento Valley Road, Suite 300
San Diego, CA 92121

       Re: aTyr Pharma, Inc.
           Registration Statement on Form S-3
           Filed August 7, 2025
           File No. 333-289360
Dear Sanjay Shukla:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Tyler Howes at 202-551-3370 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Charles Bair, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._